Roche's Avastin boosts survival of brain cancer patients
ZURICH Aug 10 (Reuters) - Swiss drugmaker Roche Holding AG said a new study of cancer drug Avastin showed it significantly extended life expectancy of people with an aggressive form of brain cancer.
The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma, Roche, the world's largest maker of cancer drugs, said in a statement on Friday.
"This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy," Roche said.
(Reporting by Andrew Thompson)
- Tweet this
- Share this
- Digg this
- Israel intensifies Gaza assault, Egyptians revise truce plan
- Obama says strains over Ukraine not leading to new Cold War with Russia
- UPDATE 2-U.S. Senate shortens transport extension, sets up clash with House
- Chinese police shoot dead dozens after attack in Xinjiang
- In rare move, Canada accuses Chinese of trying to hack govt network